Cargando…

Outcomes of first line chemotherapy in patients with chronic lymphocytic leukemia

OBJECTIVE: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease in terms of survival with and without treatment. Many chemo and immunotherapeutic agents are available to treat this indolent disease. Aim of this study was to determine the outcomes of patients with chronic lymphocytic leukemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nazir, Adil, Fawad, Ali, Sheeraz, Badar, Farhana, Siddique, Neelam, Hameed, Abdul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103136/ https://www.ncbi.nlm.nih.gov/pubmed/27882024 http://dx.doi.org/10.12669/pjms.325.10480

Ejemplares similares

CNS relapse of diffuse large B cell Lymphoma A single centre experience
por: Nazir, Adil, et al.
Publicado: (2017)

Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience
por: Ali, Sheeraz, et al.
Publicado: (2016)

Characteristics and outcomes of patients with multiple myeloma : Data from a developing country
por: Hameed, Abdul, et al.
Publicado: (2018)

Clinical predictors of anticipatory emesis in patients treated with chemotherapy at a tertiary care cancer hospital
por: Qureshi, Fawad, et al.
Publicado: (2016)

Characteristics and Outcomes of Patients with Hematological Malignancies Admitted for Intensive Care - a Single Centre Experience
por: Maqsood, Shafaq, et al.
Publicado: (2017)

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
por: Schweighofer, Carmen Diana, et al.
Publicado: (2010)

Role of rituximab in first-line treatment of chronic lymphocytic leukemia
por: Bryan, Jeffrey, et al.
Publicado: (2011)

Aggressive chronic lymphocytic leukemia masked by extensive marrow fibrosis
por: Farooq, Hareem, et al.
Publicado: (2023)

Vincristine induced neurotoxicity in children who underwent chemotherapy for acute lymphoblastic leukemia and Wilms tumor
por: Adil, Muhammad Kamran, et al.
Publicado: (2021)

Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
por: Huang, Qing, et al.
Publicado: (2022)

DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy
por: Yosifov, Deyan Yordanov, et al.
Publicado: (2020)

Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran
por: Payandeh, Mehrdad, et al.
Publicado: (2015)

Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
por: Casado, Luis Felipe, et al.
Publicado: (2016)

A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy
por: Eichenberger, Emily M., et al.
Publicado: (2019)

Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects
por: Le, Hannah, et al.
Publicado: (2021)

PB1888: EFFICACY OF FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A BAYESIANNETWORK META-ANALYSIS.
por: Chanan-Khan, A., et al.
Publicado: (2022)

Towards control of chronic lymphocytic leukemia using chemotherapy-free combinations
por: Hallek, Michael
Publicado: (2018)

Improving Outcomes for Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2020)

Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Lee, Philip, et al.
Publicado: (2022)

A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia
por: Vodárek, Pavel, et al.
Publicado: (2022)

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
por: Moreno, Carol, et al.
Publicado: (2023)

PB1922: THE FIRST REPORT OF REAL-WORLD OUTCOMES OF ZANUBRUTINIB MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Luo, Jing, et al.
Publicado: (2023)

Chronic Lymphocytic Leukemia
por: Vaisitti, Tiziana, et al.
Publicado: (2020)

Chronic lymphocytic leukemia
por: Rossi, Davide
Publicado: (2018)

The choice of first-line Chronic Myelogenous Leukemia treatment
por: Fava, Carmen, et al.
Publicado: (2015)

PB1875: TREATMENT OF YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN TUNISIA: FCR STILL STANDARD FOR FIRST-LINE THERAPY
por: Miled, W., et al.
Publicado: (2022)

P1713: VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
por: Kanevsky, D., et al.
Publicado: (2022)

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
por: Chatterjee, Anuja, et al.
Publicado: (2022)

Chronic Lymphocytic Leukemia: Real-World Data From India
por: Tejaswi, V., et al.
Publicado: (2020)

Optic neuropathy due to chronic lymphocytic leukemia: The first manifestation of the disease
por: Maleita, Diogo, et al.
Publicado: (2020)

First Case of Transformation of Immunoglobulin Heavy Chain Variable-Mutated Chronic Lymphocytic Leukemia Into Chronic Myeloid Leukemia
por: Zhang, Xueya, et al.
Publicado: (2019)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

Validation of a Mathematical Model Describing the Dynamics of Chemotherapy for Chronic Lymphocytic Leukemia In Vivo
por: Guzev, Ekaterina, et al.
Publicado: (2022)

Decreased deformability of lymphocytes in chronic lymphocytic leukemia
por: Zheng, Yi, et al.
Publicado: (2015)

Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia
por: Li, Heng, et al.
Publicado: (2017)

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
por: González-Rincón, Julia, et al.
Publicado: (2021)

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
por: Barr, Paul M., et al.
Publicado: (2022)

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
por: Lu, Xiaoxiao, et al.
Publicado: (2023)

Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression
por: Srinivasan, Vishrut K., et al.
Publicado: (2020)

Coronavirus Disease Clinical and Laboratory Parameters: Dismembering the Values Reveals Outcomes
por: Zehra, Tehzeeb, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pp3phsnvavt1kc8k6kj1psa206